A Breakthrough Brought about by Targeting KRAS(G12C): Nonconformity Is Punished

SIMPLE SUMMARY: KRAS is the most common oncogene in human cancers and has long been considered ‘‘undruggable’’—that is, until recently, when covalent inhibitors that selectively target KRAS(G12C) substitution were developed. The satisfactory results of multicenter clinical trials has led to the rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Wenjuan, Yang, Zhang, Kocher, Gregor J., Dorn, Patrick, Peng, Ren-Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774282/
https://www.ncbi.nlm.nih.gov/pubmed/35053550
http://dx.doi.org/10.3390/cancers14020390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774282/
https://www.ncbi.nlm.nih.gov/pubmed/35053550
http://dx.doi.org/10.3390/cancers14020390

Ejemplares similares